RT Journal Article
T1 Prader–Willi syndrome in a large sample from Spain:general features, obesity and regular use of psychotropicmedication.
A1 González-Domenech, Pablo José
A1 Gurpegui, Manuel
A1 González-Doménech, Carmen María
A1 Gómez-González, Susana
A1 Rustarazo, Aurora
A1 Ruiz-Nieto, Valentín
A1 Carretero, María Dolores
A1 Gutiérrez-Rojas, Luis
K1 Psicofármacos
K1 Obesidad
AB Prader-Willi syndrome (PWS), a genetically determined disorder, the most frequent cause of early onset obesity, is associated with physical and cognitive dysfunctions and behavioural disturbances; these disturbances are frequently treated with psychotropic medication. The aim of this cross sectional study was to describe the characteristics of the first large national sample of PWS in Spain and analyse the relationships of those characteristics with key demographic and clinical factors. Participants were recruited among all members of the Spanish PWS Association who agreed to take part in the study and fulfilled its inclusion criteria. Family and patient demographic features, family size and birth order, intelligence quotient, anthropometric measures, lifestyle habits, behavioural disturbances and clinical data, as well as use of psychotropic drugs and their side effects (with the UKU scale), were collected in genetically-confirmed cases of PWS. Bivariate and logistic regression analyses were used for determining the associations of demographic and clinical factors with both obesity and the regular use of psychotropic medication. The cohort included 177 participants (6-48 years), 50.8% males. Behavioural disturbances were present in a range of 75% to 93% of participants; psychotropic medication was prescribed to 81 (45.8%) of them. Number of siblings showed a direct correlation with IQ, especially among males, and inappropriate speech was more intense in only-child females. Obesity was, in parallel, strongly associated with ascending age and with not being currently under growth hormone treatment. Participants taking any psychotropic medication were characterized by more frequent age ≥30, high level of hyperactivity and a psychiatric diagnosis. Conclusion Characterisation of persons with PWS in Spain confirms their physical and behavioural phenotype and supports the long-term application of GH therapy and the rational use of psychotropic medication.
PB Wiley
YR 2024
FD 2024-01-21
LK https://hdl.handle.net/10630/29088
UL https://hdl.handle.net/10630/29088
LA eng
NO González-Domenech PJ, Gurpegui M, González-Domenech CM, Gómez-González S, Rustarazo A, Ruiz-Nieto V, Carretero MD, Gutiérrez-Rojas L. Prader-Willi syndrome in a large sample from Spain: general features, obesity and regular use of psychotropic medication. J Intellect Disabil Res. 2024 Jan 21. doi: 10.1111/jir.13123
NO Spanish Association for the Prader–Willi Syndrome.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026